LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Antisense RNA Found That Controls the X Chromosome Inactivation Regulator

By LabMedica International staff writers
Posted on 04 Nov 2015
Image: In these mouse embryo cells, XistAR RNA strands show up in red, and the Xist RNA whose production they trigger show up in green (Photo courtesy of University of Michigan).
Image: In these mouse embryo cells, XistAR RNA strands show up in red, and the Xist RNA whose production they trigger show up in green (Photo courtesy of University of Michigan).
Genomics researchers have learned how one of a female's two X chromosomes is rendered inactive, which prevents development of most diseases linked to X chromosome genetic defects.

The lncRNA (long, non-coding RNA) Xist (X-inactive specific transcript) has been known to be essential to the process of silencing one copy of the X chromosome in female embryos. Having two copies of the X chromosome is an abnormality that leads to death early of the embryo during development.

Long non-coding RNAs (long ncRNAs, lncRNA) are non-protein coding transcripts longer than 200 nucleotides. This somewhat arbitrary limit distinguishes lncRNAs from small regulatory RNAs such as microRNAs (miRNAs), short interfering RNAs (siRNAs), Piwi-interacting RNAs (piRNAs), small nucleolar RNAs (snoRNAs), and other short RNAs. LncRNAs have been found to be involved in numerous biological roles including imprinting, epigenetic gene regulation, cell cycle and apoptosis, and metastasis and prognosis in solid tumors. Most lncRNAs are expressed only in a few cells rather than whole tissues, or they are expressed at very low levels, making them difficult to study.

Investigators at the University of Michigan (Ann Arbor, USA) have now discovered how Xist is regulated. They reported in the October 19, 2015, online edition of the journal Nature Communications that they had found an Xist antisense long lncRNA, XistAR (Xist Activating RNA), which was encoded within exon one of the mouse XIST gene and was transcribed only from the inactive X chromosome. In addition, they found that the XIST gene on the otherwise “silent” X chromosome was read in both the forward and backward direction. Production of XistAR in the backward direction was required to generate Xist RNA in the forward direction and turn off the X chromosome.

“This work sheds light into how lncRNAs function, how genes and even an entire chromosome can be quieted. XistAR provides a molecular target to control gene expression—how to "wake the genes up" or reduce their activity,” said senior author Dr. Sundeep Kalantry, assistant professor of human genetics at the University of Michigan. “Exploring how the X chromosome becomes inactivated lets us know how to selectively activate it. Turning on the healthy copy of an X chromosome gene maybe a way to minimize disease risks associated with the X chromosome.”

“The control of genes by lncRNAs, often via epigenetic means, is now appreciated to occur in a wide variety of contexts, from normal physiology to diseases. On a fundamental level, it controverts the central dogma of DNA begetting RNA, which then makes proteins,” said Dr. Kalantry. “The techniques we have developed facilitate the discovery of rare RNA species in a cell. Such RNAs have been missed by high-throughput sequencing approaches, but maybe essential for cell function.”

Related Links:

University of Michigan


New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Hemodynamic System Monitor
OptoMonitor

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more